UT-MD Anderson Cancer Center: AACR - HER2 Targeted Therapy Shows Promise in Previously Treated Lung Cancers
April 28, 2025
April 28, 2025
HOUSTON, Texas, April 28 -- The University of Texas MD Anderson Cancer Center issued the following news release:
* * *
AACR: HER2 targeted therapy shows promise in previously treated lung cancers
Oral therapy is under priority review by the FDA
* Zongertinib, a HER2-targeted therapy made by Boehringer Ingelheim, demonstrated promising results in HER2-mutant lung cancer.
* These cancers are associated with resistance to standard th . . .
* * *
AACR: HER2 targeted therapy shows promise in previously treated lung cancers
Oral therapy is under priority review by the FDA
* Zongertinib, a HER2-targeted therapy made by Boehringer Ingelheim, demonstrated promising results in HER2-mutant lung cancer.
* These cancers are associated with resistance to standard th . . .